Tema Oncology ETF (NASDAQ:CANC) Short Interest Update

Tema Oncology ETF (NASDAQ:CANC) was the target of a large increase in short interest in August. As of August 31st, there was short interest totaling 22,352 shares, an increase of 108.9% from the August 15th total of 10,698 shares. Currently, 0.5% of the company’s stock are short sold. Based on an average daily trading volume, of 22,950 shares, the days-to-cover ratio is presently 1.0 days.

Tema Oncology ETF Price Performance

NASDAQ:CANC traded up $0.58 during mid-day trading on Monday, reaching $42.11. The stock had a trading volume of 11,475 shares, compared to its average volume of 31,157. The stock has a market cap of $200.87 million, a P/E ratio of 20.39 and a beta of 0.69. The business’s 50 day moving average is $42.47 and its 200 day moving average is $39.32. Tema Oncology ETF has a fifty-two week low of $26.62 and a fifty-two week high of $47.00.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of the business. Thrivent Financial for Lutherans lifted its stake in shares of Tema Oncology ETF by 891.1% in the 4th quarter. Thrivent Financial for Lutherans now owns 1,461,649 shares of the company’s stock valued at $50,747,000 after purchasing an additional 1,314,177 shares during the last quarter. Jane Street Group LLC acquired a new position in Tema Oncology ETF during the fourth quarter worth $1,100,000. Flow Traders U.S. LLC acquired a new stake in shares of Tema Oncology ETF in the third quarter worth about $630,000. LPL Financial LLC bought a new stake in shares of Tema Oncology ETF during the 4th quarter worth about $278,000. Finally, Roxbury Financial LLC boosted its stake in shares of Tema Oncology ETF by 326.4% during the 2nd quarter. Roxbury Financial LLC now owns 3,940 shares of the company’s stock worth $162,000 after acquiring an additional 3,016 shares in the last quarter.

About Tema Oncology ETF

The Tema Oncology ETF (CANC) is an exchange-traded fund that mostly invests in health care equity. The fund is actively managed, investing in stocks of companies focused on cancer treatment and management from issuers all around the world. The fund uses a bottom-up approach to select pioneering companies at perceived attractive valuations CANC was launched on Aug 15, 2023 and is issued by Tema.